Katia J. Bruxvoort, PhD, MPH

University of Alabama at Birmingham

Disclosure(s): Dynavax: Grant/Research Support; Gilead: Grant/Research Support; Glaxosmithkline: Grant/Research Support; Moderna: Grant/Research Support; Pfizer: Grant/Research Support; Seqirus: Grant/Research Support

Poster(s):

• 115 - Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 219 - A Randomized, Double-Masked, Placebo-Controlled Phase IIB Trial of Azithromycin and Trimethoprim-Sulfamethoxazole as Bacterial STI Prophylaxis in Pregnant Women with HIV
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 2232 - Association between Inappropriate Empiric Therapy (IET) and 30-Day Emergency Department/Inpatient (ED/IP) Visits Among Adult Outpatients (OPs) with Complicated Urinary Tract Infections (cUTIs)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2233 - Clinical Risk Scores (CRSs) to Predict Resistance to Trimethoprim-Sulfamethoxazole (TMP-SMX), Fluoroquinolone (FQ), Nitrofurantoin (NIT), or Third Generation Cephalosporins (3GC) among Adult Outpatients (OPs) with Complicated Urinary Tract Infections (cUTIs)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET